Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Panel Reviewing WHO Response to Swine Flu

By Drug Discovery Trends Editor | May 24, 2010

GENEVA (AP) – An expert panel investigating the World Health Organization’s response to last year’s swine flu outbreak said Wednesday it wants to see confidential exchanges between the U.N. body and drug companies.

The 29-member panel will seek WHO records and correspondence from before and after the H1N1 strain was declared a pandemic in June, said committee chairman Harvey Fineberg, who is also president of the Institute of Medicine in Washington.

“We will want to have access to certain confidential documents that may be in place here at WHO or elsewhere,” Fineberg told reporters in Geneva.

The documents include “contractual or letters of understanding” between the pharmaceutical industry and WHO, he said. “Some of the agreements with industry that we would like to examine have been considered confidential,” but so far all of the panel’s requests have been met, he said.

WHO spokesman Gregory Hartl said he couldn’t immediately comment.

Under criticism for how the outbreak was handled, WHO Director-General Margaret Chan convened the panel last month and urged its members to conduct a “credible and independent review” that she promised would be transparent.

The Geneva-based agency has denied allegations that it gave pharmaceutical companies privileged access to national decision-makers.

Governments around the world spent millions of dollars (euros) buying antiviral drugs and flu vaccines in anticipation of a serious outbreak that never happened.

Among the companies that benefited was Switzerland’s Roche Group, which saw sales of its Tamiflu antiviral medication jump by 2 billion Swiss francs ($1.74 billion) last year. British firm GlaxoSmithKline PLC sold both vaccines and its antiviral Relenza, while France’s Sanofi-Aventis SA and U.S.-based Baxter International made vaccines. Some companies donated medicine to poor countries.

WHO has confirmed 18,036 deaths from the H1N1 strain over the past year – far fewer than would have died from seasonal flu during the same period.

Chan said this week at a meeting of WHO’s 193 member states that the world had been “just plain lucky” that swine flu wasn’t deadlier.

The panel’s final report is expected to be finished next year, and will be made public, Fineberg said.

Date: May 19, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE